1 month UBS Group Begins Coverage on Perspective Therapeutics (NYSE:CATX)MarketBeat
UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday. They issued a “buy” rating and a $20.00 price objective for the company.
X